[1] Longo DL.Hepatocellular Carcinoma[J]. N Engl J Med, 2019, 380(15): 1450-1462.
[2] Siegel RL, Miller KD, Jemal A.Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1): 7-30.
[3] Center MM, Jemal A.International trends in liver cancer incidence rates[J]. Cancer Epidemiol Biomarkers Prev, 2011, 20(11):2362-2368.
[4] Forner A, Reig ME, de Lope CR, et al. Current strategy for staging and treatment: the BCLC update and future prospects[J]. Semin Liver Dis, 2010, 30(1): 61-74.
[5] 中国医师协会肝癌专业委员会. 肝细胞癌合并门静脉癌栓多学科诊治中国专家共识(2018年版)[J]. 临床肝胆病杂志, 2019, 35(4): 737-743.
[6] Zhou J, Sun H, Wang Z, et al.Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition)[J]. Liver Cancer, 2018, 7(3): 235-260.
[7] Galle PR, Forner A, Llovet JM, et al.EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236.
[8] Julie K. Heimbach LMKR, Andrew X. Zhu MHMA.AASLD Guidelines for the Treatment of Hepatocellular Carcinoma[J]. Hepatology, 2018, 67(1): 358-380.
[9] 王晓航, 朱向高, 王洪智,等. 放疗在原发性肝癌治疗中的新证据[J]. 肝癌电子杂志, 2018, 5(02):8-12.
[10] Zhang T, Zhao Y, Wang Z, et al.Efficacy and Safety of Intensity-Modulated Radiotherapy Following Transarterial Chemoembolization in Patients With Unresectable Hepatocellular Carcinoma[J]. Medicine, 2016, 95(21): e3789.
[11] Meng MB, Cui YL, Lu Y, et al.Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: a systematic review and meta-analysis[J]. Radiother Oncol, 2009, 92(2):184-194.
[12] Zou L, Zhang B, Chang Q, et al.3D conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma[J]. World J Gastroenterol,2014,20(45): 17227-17234.
[13] Huo YR, Eslick GD.Transcatheter Arterial Chemoembolization Plus Radiotherapy Compared With Chemoembolization Alone for Hepatocellular Carcinoma[J]. JAMA Oncology, 2015, 1(6): 756.
[14] 程树群, 吴孟超, 陈汉, 等. 肝癌门静脉癌栓分型的影像学意义[J]. 中华普通外科杂志, 2004, 19(4):200-201.
[15] Josep M. Llovet MDSR, Philip Hilgard MDEG, Andre Cosme De Oliveira MDAS, et al. Sorafenib in Advanced Hepatocellular Carcinoma[J]. N Engl J Med, 2008, 359: 378-390.
[16] Yamada K, Izaki K, Sugimoto K, et al.et al. Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma[J]. Int J Radiat Oncol Biol Phys, 2003, 57(1): 113-119.
[17] Huang YJ, Hsu HC, Wang CY, et al.The treatment responses in cases of radiation therapy to portal vein thrombosis in advanced hepatocellular carcinoma[J]. Int J Radiat Oncol Biol Phys, 2009, 73(4): 1155-1163.
[18] Kim GA, Shim JH, Yoon SM, et al.Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis[J]. J Vasc Interv Radiol, 2015, 26(3): 320-329.
[19] Im JH, Yoon SM, Park HC, et al.Radiotherapeutic strategies for hepatocellular carcinoma with portal vein tumour thrombosis in a hepatitis B endemic area[J]. Liver Int, 2017, 37(1): 90-100.
[20] Zhao Q, Zhu K, Yue J, et al.Comparison of intra-arterial chemoembolization with and without radiotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a meta-analysis[J]. Ther Clin Risk Manag, 2017, 13: 21-31.
[21] Yoon SM, Ryoo B, Lee SJ, et al.Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion[J]. JAMA Oncology, 2018, 4(5): 661.
[22] Wei X, Jiang Y, Zhang X, et al.Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study[J]. J Clin Oncol, 2019, 37(24): 2141-2151.
[23] Seo YS, Kim MS, Yoo SY, et al.Preliminary result of stereotactic body radiotherapy as a local salvage treatment for inoperable hepatocellular carcinoma[J]. J Surg Oncol, 2010, 102(3): 209-214.
[24] Bujold A, Massey CA, Kim JJ, et al.Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma[J]. J Clin Oncol, 2013, 31(13): 1631-1639.
[25] Wong TC, Chiang C, Lee A, et al.Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis[J]. Surg Oncol, 2019, 28: 228-235.
[26] Yoon HI, Lee IJ, Han K, et al.Improved oncologic outcomes with image-guided intensity-modulated radiation therapy using helical tomotherapy in locally advanced hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2014, 140(9): 1595-1605.
[27] Hou J, Zeng Z, Wang B, et al.High dose radiotherapy with image-guided hypo-IMRT for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombi is more feasible and efficacious than conventional 3D-CRT[J]. Jpn J Clin Oncol, 2016, 46(4): 357-362.
[28] Kuo Y, Chiu Y, Shih W, et al.Volumetric intensity-modulated Arc (RapidArc) therapy for primary hepatocellular carcinoma: comparison with intensity-modulated radiotherapy and 3-D conformal radiotherapy[J]. Radiation Oncology, 2011, 6(1): 76-84.
[29] Park JM, Kim K, Chie EK, et al.RapidArc vs intensity-modulated radiation therapy for hepatocellular carcinoma:a comparative planning study[J]. Br J Radiol, 2012, 85(1015): e323-329.
[30] Song JH, Son SH, Kay CS, et al.Reducing the probability of radiation-induced hepatic toxicity by hanging the treatment modality from helical tomotherapy to fixed-beam intensity-modulated radiotherapy[J].Oncotarget, 2015, 6(32): 33952-33960.
[31] Bowen SR, Sainic J, Chapmana TR, et al.Differential hepatic avoidance radiation therapy: Proof of concept in hepatocellular carcinoma patients[J]. Radiother Oncol, 2015, 115(2): 203-210. |
